quinta-feira, 16 de abril de 2026
dev/financiero
S&P 500N/AN/ANASDAQN/AN/AIBEX 35N/AN/ASTOXX 600N/AN/AEUR/USDN/AN/AGBP/USDN/AN/AUSD/MXNN/AN/ABTCN/AN/AETHN/AN/AOroN/AN/A
S&P 500N/AN/ANASDAQN/AN/AIBEX 35N/AN/ASTOXX 600N/AN/AEUR/USDN/AN/AGBP/USDN/AN/AUSD/MXNN/AN/ABTCN/AN/AETHN/AN/AOroN/AN/A
Capa/Portada
Financial TimesPortada

China to drive a weight-loss drug price war

The active ingredient semaglutide is starting to lose patent protection and China can produce GLP-1 related treatments at scale

R
Redacción
Redação · Hace 19 h
Leitura 2 min
The active ingredient semaglutide is starting to lose patent protection and China can produce GLP-1 related treatments at scale
Ler a nota completa em Financial Times